A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

Chimeric antigen receptor (CAR)–modified T-cell therapies targeting CD19 represent a new treatment option for patients with relapsed/refractory (R/R) B-cell malignancies. However, CAR T-cell therapy fails to elicit durable responses in a significant fraction of patients. Limited in vivo proliferatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirayama, Alexandre V., Chou, Cassie K., Miyazaki, Takahiro, Steinmetz, Rachel N., Di, Henna A., Fraessle, Simon P., Gauthier, Jordan, Fiorenza, Salvatore, Hawkins, Reed M., Overwijk, Willem W., Riddell, Stanley R., Marcondes, Mario Q., Turtle, Cameron J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242497/
https://www.ncbi.nlm.nih.gov/pubmed/36332004
http://dx.doi.org/10.1182/bloodadvances.2022008697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242497/
https://www.ncbi.nlm.nih.gov/pubmed/36332004
http://dx.doi.org/10.1182/bloodadvances.2022008697

Ejemplares similares